Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants
- 1 January 2017
- journal article
- research article
- Published by Elsevier BV in Journal of Affective Disorders
- Vol. 208, 6-14
- https://doi.org/10.1016/j.jad.2016.08.029
Abstract
No abstract availableFunding Information
- PharmoRx Therapeutics
This publication has 37 references indexed in Scilit:
- Opioid receptors: distinct roles in mood disordersTrends in Neurosciences, 2013
- RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ)CNS Neuroscience & Therapeutics, 2010
- Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot StudyPain Medicine, 2009
- Non‐stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll‐like receptor 4 (TLR4)European Journal of Neuroscience, 2008
- High-Affinity Naloxone Binding to Filamin A Prevents Mu Opioid Receptor–Gs Coupling Underlying Opioid Tolerance and DependencePLOS ONE, 2008
- Dopaminergic mechanism of antidepressant action in depressed patientsJournal of Affective Disorders, 2005
- The opioid antagonist naltrexone blocks acute endotoxic shock by inhibiting tumor necrosis factor-α productionBrain, Behavior, and Immunity, 2004
- The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluationPsychological Medicine, 2004
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960